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Abstract
Background: Nebulised antibiotics are frequently used for the prevention or
treatment of ventilator-associated pneumonia. Many factors may influence
pulmonary drug concentrations with inaccurate dosing schedules potentially leading
to therapeutic failure and/or the emergence of antibiotic resistance. We describe a
research pathway for studying the pharmacokinetics of a nebulised antibiotic during
mechanical ventilation using in vitro methods and ovine models, using tobramycin
as the study antibiotic.
Methods: In vitro studies using a laser diffractometer and a bacterial-viral filter were
used to measure the effect of the type and size of tracheal tubes and antibiotic
concentration on the particle size distribution of the tobramycin 400 mg (4 ml;
100 mg/ml) and 160 mg (4 ml, 40 mg/ml) aerosol and nebulised mass delivered. To
compare the regional drug distribution in the lung of two routes (intravenous and
nebulised) of drug administration of tobramycin 400 mg, technetium-99m-labelled
tobramycin 400 mg with planar nuclear medicine imaging was used in a
mechanically ventilated ovine model. To measure tobramycin concentrations by
intravenous and nebulised tobramycin 400 mg (4 ml, 100 mg/ml) administration in
the lung interstitial space (ISF) fluid and blood of mechanically ventilated sheep, the
microdialysis technique was used over an 8-h duration.
Results: Tobramycin 100 mg/ml achieved a higher lung dose (121.3 mg) compared
to 40 mg/ml (41.3 mg) solution. The imaging study with labelled tobramycin
indicated that nebulised tobramycin distributed more extensively into each lung
zone of the mechanically ventilated sheep than intravenous administration. A higher
lung ISF peak concentration of tobramycin was observed with nebulised tobramycin
(40.8 mg/l) compared to intravenous route (19.0 mg/l).
Conclusions: The research methods appear promising to describe lung
pharmacokinetics for formulations intended for nebulisation during mechanical
ventilation. These methods need further validation in an experimental pneumonia
model to be able to contribute toward optimising dosing regimens to inform clinical
trials and/or clinical use.
(Continued on next page)
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Background
Ventilator-associated pneumonia (VAP) is common in intensive care patients and is as-
sociated with high morbidity and mortality rates [1]. To improve outcomes, nebulised
antibiotic therapy has been recommended for prevention [2] and treatment of VAP [3].
However, there is controversy, with recent guidelines not recommending the use of
nebulised antibiotics, citing a lack of robust effectiveness data, possibly due to inad-
equate trial designs and/or ineffective drug delivery [4]. Antibiotic nebulisation can po-
tentially be a viable alternative to conventional therapy for lung infection because if
administered appropriately, it should enable high lung antibiotic concentrations with-
out significant side effects [5]. However, there are a number of factors involved in
achieving optimal delivery [6, 7], which need to be characterised to ensure desired con-
centrations are achieved. These include physicochemical properties of the antibiotics,
tracheal tube size and type [7–9], besides factors associated with mechanical ventilation
such as ventilator settings, circuit-related factors, nebuliser factors and patient-related
factors such as airway geometry and patency [7]. Due to methodological limitations,
the pharmacokinetics (PK) of nebulised antibiotics during mechanical ventilation is not
well understood.
For effective nebulisation therapy with mechanical ventilation, it is essential to opti-
mise these factors. Vital information regarding drug deposition, metabolism, absorp-
tion, kinetic profile and tolerability should be considered when designing optimised
dosing regimens [10]. The clinical environment provides limited opportunities to accur-
ately study these numerous factors affecting nebulised drug delivery and lung concen-
tration of antibiotics [10]. Hence, in vitro studies are essential to study these factors, in
isolation and in combination [11]. Further to this, animal models can allow the ma-
nipulation of variables and study of their effects, which may not be feasible in human
subjects [12]. Although small animals have been extensively used for these purposes
[13, 14], when the study involves factors that may significantly affect drug delivery such
as the airway and lung anatomy as well as circulatory parameters, large animals are
preferable as they more accurately represent the human scenario [15, 16]. The patho-
physiological changes that occur in respiratory diseases could influence the PK of nebu-
lised antibiotics [7]. Sheep are considered an appropriate large animal model to study
pulmonary PK associated with different devices and/or formulations [10] in healthy
and in experimental pneumonia models [17, 18]. In this paper, we describe an approach
to providing a detailed characterisation of pulmonary PK of nebulised drug delivery
using a combination of in vitro and ovine studies.
The specific aims of this research are:
1. To calibrate the nebulised delivery system during mechanical ventilation.
2. To quantify and compare the regional pulmonary distribution when administered
via intravenous and nebulised routes during mechanical ventilation in a healthy
ovine model.
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3. To calibrate the microdialysis system and its application to quantify and compare
lung interstitial fluid (ISF) concentrations of tobramycin when administered via
intravenous and nebulised routes during mechanical ventilation in a healthy
ovine model.
Methods
The program of research comprises of complementary studies investigating different
aspects of nebulised antibiotic therapy with a view to addressing key questions (Table 1).
Each individual sub-study is described in detail below.
Calibrating the nebulised delivery system during mechanical ventilation
Two experimental techniques were employed for this purpose.
Table 1 Overview of the research pathway with the study components aimed at characterising
the pharmacokinetics of nebulised tobramycin
Research pathway
Study 1. In vitro particle
sizing and inhaled
mass study
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of the flow rates
• ELF concentration and
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and PK
dv10 volume diameter under which 10% of the sample resides; dv50 volume median diameter; dv90 volume diameter
under which 90% of the sample resides; FPF fine particle fraction (particle size 1 to 5 μm); inhaled drug percent percent
quantity of drug in the inhaled mass filter at the end of the tracheal tube post-nebulisation; lung dose the product of FPF
and inhaled drug mass (mg); ELF epithelial lining fluid derived from urea levels; ISF interstitial space fluid;
PK pharmacokinetics
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Aerosol particle size distribution
Equipment We used an adult-use mechanical ventilator and circuits (Puritan Bennett
840 ventilator, Covidien-Medtronic, Mansfield, MA) in conjunction with a disposable
vibrating mesh nebuliser (VMN) (Aeroneb pro, Aerogen, Inc., Galway, Ireland) placed
in the inspiratory limb of the circuit as per the recommendations [19]. Although there
are a number of delivery devices available, VMN is recommended for nebulised
antibiotic therapy in mechanically ventilated patients [19, 20]. We investigated the ef-
fects of different concentrations of tobramycin (Tobra-day, Phebra) 100 mg/ml and
40 mg/ml (Tobramycin PF, Pfizer, Australia) on the nebulisation characteristics. We
also investigated the effects of different types of tracheal tubes (endotracheal tube vs
tracheostomy tube; Portex, Smiths Medical International Ltd., UK) with tube size
9.0 mm internal diameter.
Study method As ventilator settings can affect aerosol drug delivery [7], the parame-
ters set here were adjusted for their use in the ovine in vivo studies later. Ventilator pa-
rameters were fixed for all the in vitro experiments with a tidal volume of 500 ml,
respiratory rate 14/min, square wave flow pattern, flow rate 40 lpm, positive
end-expiratory pressure (PEEP) = 5 and FiO2 = 0.21.
As recommended by expert consensus, humidification was turned off for the experi-
ments [21]. The tips of the tracheal tubes were placed in the receptacle of the laser dif-
fractometer (Spraytec, Malvern Instruments, UK) using a silicone adaptor. The
principle of the laser diffraction technique is shown in Fig. 1. The circuit was closed
using an adult test lung (Dräger Medical, Lubeck, Germany) thus enabling continuous
operation. The nebuliser was then filled with 4 ml tobramycin 100 mg/ml (400 mg)
and then repeated with 4 ml of 40 mg/ml concentration (160 mg). Nebulisation was
considered to be complete when no mist was visible from the nebuliser. The nebuliser
and bacterial filter were changed after every experiment as per the guidelines [19].
Figure 2a demonstrates the study set-up in the laboratory.
Data collection and analysis The following data were collected: baseline temperature,
pH and viscosity of the tobramycin solution and nebulisation time. The viscosity of the
Fig. 1 Principle of laser diffraction technique for particle sizing
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tobramycin solution was determined at a constant temperature of 25 °C using a DHR-3
Rheometer (TA Instruments, USA). Particle size distributions were expressed as dv10
(volume diameter under which 10% of the sample resides), dv50 (volume median diam-
eter) and dv90 (volume diameter under which 90% of the sample resides). In addition to
dv10, dv50 and dv90, the percentages of particles between sizes 1 and 5 μm (the sizes
conventionally considered for lung deposition) obtained from the laser diffractometer
were included in this work.
In vitro nebulised mass study
Equipment Adult-use mechanical ventilator, VMN, endotracheal tubes and tracheos-
tomy tubes and tobramycin were used as per the particle size distribution study de-
scribed above. In addition, respiratory (bacterial and viral) filters (filter pads, Fisher and
Paykel, Auckland, New Zealand) were used.
b
a
Fig. 2 a Experimental set-up for particle sizing experiments. b Experimental set-up for inhaled mass experiments
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Study method Using a previously described methodology [22], we used the same
set-up as described previously and insert the tip of the tracheal tube into a respiratory
(bacterial and viral) filter (filter pads, Fisher and Paykel, Auckland, New Zealand). The
circuit was closed using an adult test lung (Dräger Medical, Lubeck, Germany) thus
allowing continuous operation. The nebuliser was filled with 4 ml tobramycin
100 mg/ml (400 mg) instilled with the nebulisation process to continue until there
is no visible mist from the nebuliser. The ventilator was paused whilst the filter
was removed from the circuit and stored at − 80 °C for drug assay using liquid
chromatography with tandem mass spectrometry (LC/MS-MS). The process was repeated
with 4 ml tobramycin 40 mg/ml (160 mg). The nebuliser was weighed before and after
nebulisation to describe residual drug quantity. The experiment was done with each of
the tracheal tubes as previously mentioned. Each experiment was repeated in triplicate.
The nebuliser and bacterial filter were changed after every experiment as per the guide-
lines [19]. The study set-up was as shown in Fig. 2b.
Sample and data analysis Tobramycin was extracted from the filter using water in a
sonication bath, stored at − 80 °C and analysed later using liquid
chromatography-tandem mass spectrometry (LC-MS/MS) as described later. The
amount of drug was reported as milligrams (mg) of tobramycin. The percentage of the
nebulised drug on the filter was calculated and expressed with ranges. Combined data
from the particle sizing and nebulised mass study was used to describe the lung dose,
i.e. the amount of drug in the effective particle size range for distal lung deposition.
Development of an ovine model for aerosol studies
Design
We used a healthy ovine model to assess the regional drug deposition and lung ISF
concentrations of intravenously and nebulised tobramycin.
Ethics
All the ovine studies have been ethically approved by the Queensland University of
Technology animal ethics committee approval (Approval no. 1100000052; lung ISF
study) and University of Queensland animal ethics committee approval (Approval no.
SOM/268/16/RBWH; regional distribution studies).
Operating room set up
The basic operating room set-up and the anaesthesia and instrumentation components
of the study were the same for the regional drug distribution study and the tobramycin
concentration in the lung ISF study.
The operating room was equipped to manage and monitor for the animals’ health
and well-being. A ‘head box’ or suspender was used to stabilise and immobilise the
head whilst being sedated and mechanically ventilated in a prone position. Syringe
drivers and infusion pumps were used for fluid infusions and anaesthesia maintenance.
Precision microdialysis pumps (CMA 107, CMA microdialysis, Solna, Sweden) were
used for microdialysis. A fibreoptic bronchoscope ((Pentax FB15TV, Philips, Tokyo,
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Japan) was used to obtain mini-bronchoalveolar lavage (BAL) samples. A qualified vet
supervised the procedure at all times.
Anaesthesia and instrumentation
Pre-study The veterinary specialist examined all Merino sheeps, and baseline blood
samples were collected with only healthy Merino sheep weighing 40 to 50 kg se-
lected for the study. The sheeps were fasted overnight and were led to the operat-
ing room in a protective sling with face, neck and chest area shaved.
Venous access, anaesthesia induction, airway access and mechanical ventilation
Using aseptic technique, a central venous line was inserted through the right jugu-
lar vein under local anaesthesia. Anaesthesia was commenced using induction
agents, midazolam 0.5 mg/kg and alfaxalone 3 mg/kg (Jurox Pty Ltd., Hunter Val-
ley, Australia). Orotracheal intubation was performed using an endotracheal tube
(Portex, Smiths Medical, London, UK). Tracheal intubation was confirmed using a
colorimeter and mechanical ventilation commenced. Ventilator parameters used
throughout the experiment fulfilled the Acute Respiratory Distress Syndrome Net-
work criteria for lung protective ventilation [23]. Initial ventilator settings for all
the sheeps were respiratory rate 14 breaths per minute, tidal volume 500 ml, PEEP
5 cm H2O and fraction of inspired oxygen (FiO2) 0.21. During nebulisation, square
wave flow pattern was applied, and the humidifier was turned off. Respiratory rate
and FiO2 were adjusted according to arterial blood gas (ABG) results to maintain
normal parameters. Due to the long length of the sheep airway, it was necessary to
perform a tracheostomy to represent the human airway. This was performed with
an aseptic technique using a size 9 tracheostomy tube (Portex, Smiths Medical,
London, UK) and confirmed using bronchoscope and capnography. The airway was
assessed using bronchoscopy for any anatomical variation or pathological abnor-
mality. The animal was subsequently positioned in a prone position. Anaesthesia
was maintained using ketamine 3–5 mg/kg/h, midazolam 0.25–0.5 mg/kg/h and
alfaxalone 4–6 mg/kg/h infusion titrated to effect. Hydration was maintained using
Hartmann’s solution at the rate of 2 ml/kg. The animal was kept warm using
warming blankets. The operating room set-up, anaesthesia and instrumentation
were common to the two ovine studies—regional drug distribution and
microdialysis.
Monitoring The sheep had routine monitoring using ECG, arterial blood pressure
(ABP), end-tidal carbon dioxide monitor (ETCO2), pulse oximetry and central ven-
ous pressure (CVP) monitoring. An invasive arterial line was inserted in the facial
artery using a cut-down method for the ABP monitoring and ABG sampling. Vital
physiological data was recorded using Marquette Solar 8000 monitor (GE Health-
care, Little Chalfont, UK). A urinary catheter and orogastric tube were also
inserted. Regular ABGs (two hourly) were obtained to confirm the adequacy of
ventilation and other parameters such as electrolytes, glucose and lactate levels.
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Comparing regional pulmonary distribution of intravenous and nebulised tobramycin
during mechanical ventilation
Computed tomography scan
Following adequate instrumentation, a CT scan of the chest was performed to confirm
normal lung anatomy, and the images were used to obtain a region of interest (ROI)
during image analysis. The ROI provides the lung outline for superimposition onto the
gamma camera images for subsequent analysis.
Drug administration
Nebulisation Using a disposable (VMN) (Aeroneb pro, Aerogen, Inc., Galway, Ireland)
in the inspiratory limb of the ventilator circuit, tobramycin 400 mg (100 mg/ml) la-
belled with technetium-99m was nebulised until no further mist is visible. Previous
studies have shown that the aerosol characteristics of labelled tobramycin are similar to
that of unlabelled tobramycin [24].
Intravenous Technetium-99m-labelled tobramycin 400 mg was injected via a central
venous line as a 30-min infusion. The lumen was flushed with 100 ml of 0.9% saline.
Image acquisition A single-head gamma camera (GE Starcam 600 XR/T Gamma
Camera, GE Healthcare Global Diagnostic Imaging, Waukesha, WI, USA) was used to
acquire planar images. The CT scan and the gamma camera scan equipment were lo-
cated within the same research facility. Dynamic (10 s frames) and static scans were ob-
tained. Images were acquired from lateral, dorsal and ventral aspects. Blood samples at
predetermined intervals were obtained to coincide with the scans. Radiation count in
the nebuliser and the syringe was performed before and after the nebulisation and
intravenous administration, respectively, to define the dose and radioactivity
administered.
Euthanasia and tissue sampling At the completion of the study, the sheep was eutha-
nized using sodium pentobarbitone (295 mg/ml, 0.5 ml/kg). Death was confirmed by
loss of cardiac electrical activity and ABP trace. After euthanasia, the organs were sur-
gically retrieved. Direct tissue sampling from pre-defined regions of the lungs, liver,
both kidneys and urine was performed. The remains of the animals were frozen and
stored until disposed of via incineration.
Data analysis The images were analysed and reported as radioactivity distribution into
peripheral to central ratio (P/C ratio), also known as ‘penetration index’ for the nebu-
lised tobramycin group. For this analysis, the central region represents the conducting
airways, and the peripheral represents the alveoli. Parameters used to compare the
intravenous and nebulised route of administration include dorsal to ventral ratio, right
to left lung ratio and upper/middle/lower lung zone distribution. The quantitative ana-
lysis included describing the radioactivity in per gram of pulmonary and
extra-pulmonary tissue. Blood radioactivity was compared between the two groups as a
surrogate measure of drug level in the systemic circulation.
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Calibration of the microdialysis system using in vitro microdialysis recovery study
Equipment
The study used fresh frozen plasma and a magnetic stirrer CMA 63 microdialysis cath-
eters (molecular weight cut-off of 20 kDa; an outer diameter of 0.6 mm and a mem-
brane length of 30 mm; CMA Microdialysis AB, Stockholm, Sweden), CMA 107
precision microinfusion pump (CMA Microdialysis AB, Stockholm, Sweden) and
Cole-Parmer two-syringe infusion pump 230 VAC CE (John Morris Group, Chatswood,
Australia).
Study method
Microdialysis probes were perfused with Ringer’s solution at three different flow rates
1, 1.5 and 2 μl/min using the precision pump. The membranes of the microdialysis
probes were immersed in 50 ml solution of 5 μg/mL of tobramycin and 5 μg/mL
vancomycin concentrations. The samples were collected at 20-min intervals for
100 min with experiments repeated in triplicate.
Sample analysis
Samples were stored at − 80 °C and assayed using LC-MS/MS methods described
previously.
Recovery rates were expressed as relative recovery (RR):
RR %ð Þ ¼ 1−Cdialysate=Csolution
  100
where Cdialysate = concentration of antibiotic in the microdialysate and Csolution = con-
centration of antibiotic in the test solution.
Figure 3a, b describes the principles of microdialysis when used for the study of in-
haled antibiotics and intravenous antibiotics, respectively. The principles have been de-
scribed in detail previously [25].
Comparing lung ISF concentrations of intravenous and nebulised tobramycin
Microdialysis catheter priming and set-up
Various factors influence in vivo recovery of analytes; hence, in addition to in vitro
studies, it is essential to perform in vivo recovery [25]. Methods for in vivo recovery
calculations have been described in the literature [26]. Internal indicator technique was
used in this study. The perfusate for microdialysis was prepared using 0.1 ml (4 mg) of
gentamicin 80 mg/2 ml vial. This was injected into a 1-l bag of Hartmann’s solution to
make up a concentration of 4 μg/ml which was then be used as the perfusate for the
catheters. Gentamicin was used as an internal standard to enable in vivo recovery cal-
culations and was chosen due to similarities with tobramycin (molecular weight of gen-
tamicin = 467 vs tobramycin = 477 g/mol). Using CMA 107 battery pumps, the
microdialysis catheters were primed with the perfusate solution at a rate of 5 μl/min
for 10 min. The catheters were then inserted, and the perfusate rate was reduced to
1 μl/min for the remainder of the experiment. Once inserted, the catheters were per-
fused for a period of 1 h to achieve a steady state equilibrium.
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Insertion of microdialysis catheters
After anaesthesia induction and instrumentation, bilateral thoracotomies were per-
formed in the fifth intercostal space exposing the interlobar fissures. A CMA 63 micro-
dialysis catheter (CMA Microdialysis AB, Stockholm, Sweden) with a molecular weight
cut-off of 20 kDa, an outer diameter of 0.6 mm and a membrane length of 30 mm was
used. Four microdialysis catheters were inserted, in the right upper and lower and the
left upper and lower lobes using an introducer needle under direct vision. Bioglue
(Coseal surgical sealant, Cohesion technologies, US) was applied at the lung puncture
site to minimise catheter movement post-insertion. An intercostal catheter was inserted
in each of the pleural spaces and low-pressure suction applied, and the thoracotomy in-
cisions will be closed. An intravascular microdialysis catheter, CMA 64 (CMA Microdi-
alysis AB, Stockholm, Sweden) with a molecular weight cut-off 20 kDa and a
membrane length of 20 mm, was inserted in the left jugular vein through a percutan-
eously inserted 18G cannula (B. Braun Australia Pty Ltd., Bella Vista, Australia).
b
a
Fig. 3 Schematic diagram demonstrating the principle of lung microdialysis. The unidirectional perfusate
flow provides a concentration gradient for diffusion of analytes across a semi-permeable membrane placed in
the lung interstitium. The dialysate is then collected in microvials for analysis. a Principles of lung microdialysis
with nebulised antibiotics—showing higher antibiotic concentration in the alveoli. b Principles of lung
microdialysis with intravenous antibiotics—showing higher antibiotic concentration in the pulmonary arteriole
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Drug administration
Nebulisation Using a disposable (VMN) (Aeroneb pro, Aerogen, Inc., Galway, Ireland)
in the inspiratory limb of the ventilator circuit, tobramycin 400 mg (Tobra-day, Phebra
500 mg/5 ml) was nebulised. The nebulisation was continued until the visible mist
from the nebuliser stopped. A baseline pre-nebulisation microdialysis sample was col-
lected (T0).
Intravenous antibiotic administration Tobramycin 400 mg (Tobra-day, Phebra
500 mg/5 ml) was administered intravenously through the central venous line as a
30-min infusion. A baseline pre-intravenous administration, microdialysis sample was
collected (T0).
Following the drug administration (nebulised and intravenous), the samples were col-
lected at every 20 min in a microvial (CMA, Microdialysis AB) for 8 h. The samples
were stored at − 80 °C for further analysis.
Bronchoalveolar lavage A mini-BAL was performed at T = 60 min, 4 h and 7 h using
two 20 ml aliquots of normal saline as previously described [27, 28]. This procedure
was performed using a fibreoptic bronchoscope with the tip wedged in the right lower
lobe and left lower lobe bronchi. The actual epithelial lining fluid (ELF) concentrations
of tobramycin were obtained from the measured BAL fluid concentrations after correc-
tion for dilution according to the equation:
CELF ¼ CBAL UreaPLASMA=UreaBALð Þ
where CBAL corresponds to the tobramycin concentrations measured in the BAL
fluid, and UreaBAL and UreaPLASMA correspond to the concentrations of urea deter-
mined in BAL fluid and plasma, respectively. Blood samples were taken for measuring
urea to assess the adequacy of BAL.
Euthanasia, catheter inspection and organ retrieval At the completion of the study,
the sheeps were humanely euthanized using sodium pentobarbitone (295 mg/ml, dose
0.5 ml/kg). Using chest retractors, the microdialysis catheters were exposed and
inspected to confirm that the catheters remained inside the lungs throughout the pro-
cedure. The catheters were inspected for obvious evidence of damage. The lungs were
retrieved, and the sections of bilateral upper and lower lobes were visually inspected
and harvested for further drug concentration analysis. The remains of the animals were
frozen and stored until disposal via incineration.
LC-MS/MS method for sample analysis The tobramycin concentrations in microdial-
ysis samples reported were measured by an LC-MS/MS method using a simple di-
lution preparation and HILIC chromatography on a Shimadzu Nexera2 system
coupled to a Shimadzu 8030+ triple quadrupole mass spectrometer (Kyoto, Japan).
The assay method has validation for linearity (quadratic line from 0.1 to 20 μg/ml
with precision and accuracy of all calibration standards within 8%), LLOQ (preci-
sion and accuracy within 6% at 0.1 μg/mL), matrix effects (normalised matrix
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factor precision within 9% at 0.2 and 16 μg/ml) and precision and accuracy (preci-
sion and accuracy within 10% at 0.3, 2 and 16 μg/ml) using the FDA criteria for
bioanalysis [29]. Recovery data was used to calculate the corrected tobramycin con-
centrations in the microdialysate.
Statistical considerations The results were expressed as mean, median, minimum,
maximum and standard deviation. For the in vitro particle size and inhaled mass study,
multiple linear regression was used to estimate the effect of the variables on the out-
comes. For the in vitro microdialysis recovery studies, a linear regression model using
recovery as the dependent variable and flow rate as the independent variable was ap-
plied. Similarly, the blood radioactivity levels in the ovine study were compared using
Bayesian regression analysis using a random intercept for each sheep and Bayesian p
values were obtained. These analyses were conducted using R version 3.4.2 and
WinBUGS version 1.4.3 for the Bayesian regression analysis. The individual studies
were not powered to detect statistical significance, and instead, we used confidence in-
tervals where appropriate and discuss the size of the differences in terms of their clin-
ical as well as statistical significance. The plots of summary statistics were used to
compare groups and results over time.
Results
The simulated adult mechanical ventilation model to evaluate the particle size distribution
and quantify the efficacy of the aerosol system showed that fine particle fraction (1 to
5 μm) was significantly higher for 100 mg/ml solution compared to 40 mg/ml solution
(99.4 ± 0.3% vs 82.3 ± 6%; p < 0.001). The lung dose delivered was significantly higher for
100 mg/ml solution compared to 40 mg/ml solution (132.7 ± 12.6 mg vs 39.2 ± 1.1 mg; p
< 0.001). Nebulisation duration was significantly higher for the 100 mg/ml solution com-
pared to 40 mg/ml solution for endotracheal tube (18.56 ± 2.36 vs 7.88 ± 1.08 min; p <
0.001) and tracheostomy tube (14.63 ± 1.14 vs 12 ± 1.4 min; p < 0.001). Tracheal tube type
had a minimal effect which was not statistically significant, on the aerosol delivery param-
eters. Other parameters like dv10 and dv95 were not statistically different. Table 2
Table 2 Comparative characteristics between tobramycin 40 and 100 mg/ml solutions
Parameters Tobramycin 40 mg/ml Tobramycin 100 mg/ml
pH 88 6.88 6.99
Viscosity (centipoise) 1.58 2.12
Duration of nebulisation (min)
Endotracheal tube 7.88 ± 1.08 18.56 ± 2.36*
Tracheostomy tube 12 ± 1.4 14.63 ± 1.14*
Dv10 (μm) 1.0 ± 0.05 1.4 ± 0.04
VMD (μm) 1.8 ± 0.2 2.1 ± 0.08
Dv95 (μm) 5.7 ± 0.2 3.6 ± 0.8
FPF (%) 82.3 ± 6 99.44 ± 0.3*
Lung dose (mg) 39.2 ± 1.1 132.7 ± 12.6*
dv10 volume diameter under which 10% of the sample resides; VMD volume median diameter under which 50% of the
particles resides; dv95 volume diameter under which 95% of the sample resides; FPF fine particle fraction (1–5 μm)
*p < 0.05
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summarises the differences between the two formulations. The experiments were per-
formed at a temperature of 25 °C.
The ovine model for the comparative regional lung distribution study between
aerosolized and intravenous tobramycin was successfully established. Female sheeps
(ewes, n = 4) were used for the study. There were no adverse events documented during
the ovine studies. For the nebulised sheep, the P/C ratio (penetration index) was 0.9 for
the right lung and 0.87 for the left lung. The blood radioactivity was significantly higher
for the sheep with intravenous tobramycin compared to that for the nebulised tobra-
mycin (209.2 ± 97.6 Mbq/ml vs 33.3 ± 5.4 Mbq/ml; p < 0.001). The right to left ratio
was 0.9 for intravenous and 0.89 for the nebulised sheep. Figure 4 shows the compara-
tive gamma camera scan images between i.v. and nebulised technetium-labelled tobra-
mycin. Table 3 shows that the liver, kidney and urine levels were lower for nebulised
compared to intravenous sheep.
Microdialysis recovery in the simulated in vivo conditions showed that relative recov-
ery for vancomycin was 32.6 ± 0.09%, 27.5 ± 0.09% and 20.7 ± 0.04% for perfusate flow
rates of 1, 1.5 and 2 μl/min, respectively. Thus, for vancomycin, the highest relative re-
covery was for a perfusate flow rate of 1 μl/min (95% CI 24.8 to 35.7%). For tobra-
mycin, the recoveries were 69 ± 3.74%, 69.5 ± 3.47% and 65 ± 3.8%, respectively. The
differences were not seen to be statistically significant.
The lung isf concentrations in the mechanically ventilated ovine model showed that
area under the concentration- time curve (mean) and peak (or maximum) concentra-
tion in the concentration- time curve (mean) for nebulized tobramycin was 313 mg-h/
liter and 535.8 mg/liter and for intravenous tobramycin the values were 90.82 mg-h/
liter and 22.2 mg/liter respectively, for intravenous tobramycin. Figure 5 shows lung
ISF concentrations with nebulised tobramycin compared to intravenous tobramycin.
For the nebulised tobramycin sheep, ELF concentration was 1.94 mg/l at 1 h and for
intravenous tobramycin sheep, and the level was 0.19 mg/l. (Table 4).
Technically the ovine model set up for the regional lung distribution and lung micro-
dialysis study was uneventful. There were no adverse events affecting the interpretation
Fig. 4 Comparative dorsal scintigraphy images of lung deposition of i.v and nebulised
radiolabelled tobramycin
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of results. We have optimised anaesthesia, ventilation, surgical instrumentation, scintig-
raphy protocols, sample collection and analyses in this model.
Discussion
This paper describes an incremental model of the study of the PK of nebulised antibi-
otics. As the lung is a heterogeneous organ, PK studies to accurately characterise drug
concentrations in the various compartments are difficult. We have used a methodo-
logical approach for the assessment of the PK of nebulised antibiotics using in vitro
and ovine models. For nebulised antibiotic administration, important PK parameters
are pulmonary deposition efficiency, regional distribution, pulmonary absorption and
residence time [6]. For therapeutic response, the dose deposited at the site of infection
in the lung is important [30] particularly the unbound concentration of the drug [6].
We studied these essential aspects of nebulised antibiotic therapy using tobramycin.
For higher concentration tobramycin (100 mg/ml), the aerosol delivery system can
deliver a higher lung dose. This is important for tobramycin and other aminoglycosides
that rely on peak (or maximum) concentration as the PK measure for drug effect.
Aerosol particle size and the aerosolized drug mass are important parameters for asses-
sing the efficacy of an aerosol delivery system [7]. Methods for the study of the aerosol
particle size distribution and nebulised mass have been summarised previously [22, 31].
We used the laser diffractometer which is a validated technique for the assessment of
aerosol particle size distribution [32] and an established technique for the nebulised
mass study [22]. Recent recommendations have been to place the VMN 10–15 cm from
the Y-piece [33]. The VMN was placed just before the Y-piece in the inspiratory limb to
mimic local and international practices [34] as well as the manufacturer’s
recommendations.
Our results suggest that mechanically ventilated sheep could be effectively used for
the study of regional lung distribution studies especially for drugs administered for
local effect on the lung diseases, e.g. infections. The distribution parameters of nebu-
lised tobramycin would support its use in lung infections especially with minimal sys-
temic and extra-pulmonary tissue levels as seen in our study. Methods of assessing
pulmonary drug distribution have been summarised in detail previously [35]. Whilst
single-photon emission computed tomography (SPECT) and positron emission tomog-
raphy (PET) provide a 3D description of the regional drug distribution in the lungs, for
most purposes, planar gamma scintigraphy is sufficient [36, 37] and feasible; therefore,
we used the gamma scintigraphy method for our study.
The results of the present microdialysis calibration study suggest that large molecules
like vancomycin have significantly reduced recovery and protein binding adversely af-
fected the recovery. Perfusate flow rates also affected relative recovery rates for
Table 3 Quantitative extra-pulmonary tissue radioactivity concentrations
Organ Nebulised tobramycin Intravenous tobramycin
Liver (Bq/g/Mbq) 76.5 2541.7
Left kidney (Bq/g/Mbq) 585.8 1048.4
Right kidney (Bq/g/Mbq) 704.2 2126.7
Urine (Bq/g/Mbq) 1479.1 7866.3
Bq/g/Mbq becquerel per gram per megabecquerel of administered dose
Dhanani et al. Intensive Care Medicine Experimental  (2018) 6:17 Page 14 of 19
tobramycin and vancomycin. Thus, microdialysis-based studies for large molecules as
well as highly protein-bound substances should be evaluated in vitro in a similar model.
By calibrating the microdialysis system, thus depending on the study drug, it will enable
the correct combination of microdialysis catheters and perfusate flow rates. The
techniques used in other studies to assess pulmonary drug concentrations used could
not inform adequately the longitudinal data desired over time. These studies have been
previously summarised [25], but most studies employed antibiotic BAL concentrations
as a surrogate [38, 39]. Some authors have used blood concentrations to perform popu-
lation PK compartmental modelling [40]. For most bacterial infections, the antibiotic
site of action is the ISF [41]. Lung microdialysis is an established technique to sample
lung ISF for the purposes of measuring antibiotic concentrations [25]. The details of
the microdialysis technique and relevant considerations have been described elsewhere
[42–45]. Recovery studies are important for the accurate calculation of the antibiotic
concentration in the microdialysis sample [26].
For tobramycin, the high lung ISF concentration achieved with nebulised route meets
the PK requirements for drug effect. Study of drugs with different PK parameters would
elucidate if the nebulised route is appropriate for therapy. Preclinical models for the
study of pulmonary drug delivery have been well described [10]. Methods such as in
Fig. 5 Comparative lung concentrations of tobramycin between nebulised and intravenous route
of administration
Table 4 Comparative epithelial lining fluid concentrations for nebulised and tobramycin sheep at
two time points, 1 and 6 h post-antibiotic administration
ELF time points Nebulised tobramycin Intravenous tobramycin
1 h (mg/l) 1.94 0.19
6 h (mg/l) 0.07 0.38
AUCELF (mg-h/l) 5.99 1.52
AUCplasma (mg-h/l) 56.88 53.60
AUClung/AUCplasma (mg-h/l) 0.11 0.03
ELF epithelial lining fluid; AUC area under the concentration-time curve
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vitro cell culture whilst providing a consistent method of assessing nebulised drugs
cannot predict the pulmonary bioavailability of the drug as it cannot assess the other
barriers to absorption [10]. In vitro cell culture method remains a viable alternative to
test for drug toxicity. Isolated perfused lung model provides an ex vivo model for drug
PK assessment but lack of tracheobronchial circulation could be a drawback in the as-
sessment of systemic absorption [10]. In vivo models provide the most thorough quan-
titative and qualitative data to inform the PK of pulmonary drug delivery [46].
As airway size and type were considered an important variable in drug deposition,
the in vitro aerosol characteristics were investigated with the size 9.0 mm I.D. tracheal
tubes as these were the tracheal tube sizes used for the in vivo studies in sheep, thus
minimising the variables in the study data.
Sheep are the ideal large animal model to study the PKs of nebulised antibiotics [12].
Their size and lung anatomical-physiological features are similar to humans [47]. By
replicating the study, data could be acquired to describe the PK profile of a wide range
of nebulised antibiotics. This adds valuable information for potential efficacy and tox-
icity of drugs and formulations. Our model can be applied to other potentially import-
ant questions and test other factors such as variations in ventilator parameters, the
distribution characteristics of newer nebulised drug formulations, novel delivery devices
and different patient parameters such as posture that might affect pulmonary drug de-
livery. There is potential for the study of other nebulised drugs where lung ISF concen-
trations are important, e.g. other anti-infectives like antiviral and antifungal agents,
chemotherapeutic agents and immunomodulatory drugs.
Future work will consist of pharmacodynamic studies in a variety of clinically import-
ant experimental pneumonia settings. This data could be used to improve the precision
and accuracy of nebulised antibiotic dosing schedules in a variety of lung infections in
the pre-clinical models. The complexity of the pathophysiological changes associated
with pneumonia makes the development and management of the animal models of ex-
perimental pneumonia challenging. Factors that need consideration include ethics, se-
lection of appropriate animal species, number of subjects, inoculation routes and
sampling issues, and the present animal model used account for some, but not all, of
these. Clinical trials using accurate information from these mechanistic and preclinical
studies could yield better therapeutic outcomes.
Conclusions
This program of research aims to apply in vitro and ovine models for the study of neb-
ulised antibiotic delivery and lung PK. This model can be used for further studies in-
volving drugs where knowledge of pulmonary drug concentration is essential.
Systematic investigation of other aspects of nebulised antibiotic therapy using this
model will introduce further refinements in nebulised antibiotic therapy thus improving
patient care and outcomes.
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